203519-88-4

Basic information

• Product Name: 4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(6-chloropyrimidin-4-yl)piperazine-1-carboxylate;4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-Carbocylic acid tert-butyl ester;1-Boc-4-(6-chloropyrimidin-4-yl)piperazine
• CAS NO: 203519-88-4
• Molecular Formula: C₁₃H₁₉ClN₄O₂
• Molecular Weight: 298.77
• Product Categories: pharmacetical
• Mol File: 203519-88-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 437.3°Cat760mmHg
• Flash Point: 218.3°C
• Appearance: /
• Density: 1.253
• Vapor Pressure: 7.54E-08mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester(203519-88-4)
• EPA Substance Registry System: 4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester(203519-88-4)

Safety Data

• Hazardous Substances Data: 203519-88-4(Hazardous Substances Data)

Usage

General Description

4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester is a chemical compound with the molecular formula C13H20ClN5O2. It is a tert-butyl ester derivative of piperazine-1-carboxylic acid, and it contains a chloro-pyrimidinyl group attached to the piperazine ring. 4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester has potential applications in medicinal chemistry and drug development, as it can serve as a building block for the synthesis of other bioactive molecules. The tert-butyl ester group can also protect the carboxylic acid functionality, allowing for easier manipulation and handling of the compound in laboratory settings. Overall, 4-(6-Chloro-pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester is a versatile chemical with important implications in the field of pharmaceutical research and development.

InChI:InChI=1/C13H19ClN4O2/c1-13(2,3)20-12(19)18-6-4-17(5-7-18)11-8-10(14)15-9-16-11/h8-9H,4-7H2,1-3H3

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 221050-88-0 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1143577-39-2 4-(2,4-difluorophenyl)-6-(piperazin-1-yl)pyrimidine 
• 1143577-41-6 4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]-N-(pyridazin-3-yl)piperazine-1-carboxamide 
• 203519-89-5 4-chloro-6-(piperazin-1-yl)pyrimidine dihydrochloride 
• 1143577-38-1 tert-butyl 4-[6-(2,4-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143577-52-9 tert-butyl 4-[6-(3-fluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143577-47-2 tert-butyl 4-[6-(2-fluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143578-12-4 tert-butyl 4-(6-phenylpyrimidin-4-yl)piperazine-1-carboxylate 
• 1143577-56-3 tert-butyl 4-[6-(4-fluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 1143577-43-8 tert-butyl 4-[6-(2,3-difluorophenyl)pyrimidin-4-yl]piperazine-1-carboxylate 
• 203519-89-5 (6-chloro-pyrimidin-4-yl)piperazine hydrochloride 

Relevant articles and documents

An efficient and scalable approach for the synthesis of piperazine based glitazone and its derivatives

A versatile and efficient synthetic approach has been developed for the synthesis of piperazine based glitazones analogous to Lobeglitazone. Desired compounds were synthesized with good yields by alkylation of piperazine substrate with various carbonyl co

Substituted pyrimidine derivatives with Akt inhibiting activity, and preparation method and application thereof

The invention relates to novel substituted pyrimidine derivatives with Akt inhibiting activity and a preparation method thereof, a pharmaceutical composition comprising the substituted pyrimidine derivatives and salts thereof, and application of the substituted pyrimidine derivatives and salts thereof in preparing drugs for preventing and/or treating tumors. The structural formula of the compounds is disclosed as Formula (I) or Formula (II). The compounds have the advantages of novel structure, outstanding Akt inhibiting activity, high safety and low preparation cost, and have favorable application prospects in preparing antineoplastic drugs.

PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of sphingosine kinase. Particularly, although not exclusively, the present invention also relates to pharmaceutical compositions comprising th